International Journal of Biomedicine. 2019;9(4):300-303.
Originally published December 15, 2019
The purpose of our study was to evaluate the effectiveness of sodium deoxyribonucleate (Derinat, solution for intramuscular injection) in combination with standard therapy in the treatment of COPD Group C patients in outpatient settings.
Materials and Methods: The study included 80 patients (43 men and 37 women) with COPD (Group C), mean age of 51.7±1.4 years. Blood sampling for the study was carried out 3 times—before the start of therapy, and on days 5 and 15. Using monoclonal antibodies, we determined the number of lyphocytes carrying markers CD3+, CD+, CD8+, and CD72+. The quality of life (QL) indicators were evaluated using the St. George’s Respiratory Questionnaire (SGRQ). For at least 15 days, patients received standard COPD therapy. All patients were divided into 2 groups: Group 1 included 41 patients who received Derinat 75 mg intramuscularly once daily for 5 days; then - 5 injections with an interval of 48 hours against the background of standard therapy. Group 2 included 39 patients who continued to receive standard COPD therapy.
Results: The inclusion of Derinat in the complex therapy of COPD contributed to the normalization of the T-cell to B-cell ratio, an increase in the number of T suppressors. Assessing the clinical effects of combination therapy with the inclusion of the studied drug, a marked decrease in shortness of breath, cough, and the amount of sputum excreted can be noted in comparison with standard therapy. The improvement of the immunological status and clinical indicators against the background of complex therapy was accompanied by an increase in QL.
- Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-128. doi: 10.1016/S0140-6736(12)61728-0.
- Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5). pii: 1900164. doi: 10.1183/13993003.00164-2019.
- O'Mahony DS, Pham U, Iyer R, Hawn TR, Liles WC. Differential constitutive and cytokine-modulated expression of human Toll–like receptors in primary neutrophils, monocytes, and macrophages. Int J Med Sci. 2008;5(1):1–8
- Yamaya M, Yasuda H, Yoshida M, Nishimura H, Nakayama K. [Treatment and prevention of COPD exacerbation]. Nihon Rinsho. 2007;65(4):734–9. [Article in Japanese].
- Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574–80.
- Zheng JP, Kang J, Huang SG, Chen P, Yao WZ, Yang L, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomized placebo-controlled study. Lancet. 2008;371(9629):2013-8. doi: 10.1016/S0140-6736(08)60869-7.
- Serebrianaia NB. [Nucleotides as regulators of the immune response]. Immunologiya. 2010;(5):273–281.[Article in Russian].
- Caramori G, Adcock IM, Di Stefano A, Chung KF. Cytokine inhibition in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:397-412. doi: 10.2147/COPD.S42544.
- Oudijk EJ, Nijhuis EH, Zwank MD, van de Graaf EA, Mager HJ, Coffer PJ, et al. Systemic inflammation in COPD visualised by gene profiling in peripheral blood neutrophils. Torax. 2005;60(7):538-44.
- Serebrianaia NB, Kalinina NM. [Nucleotide regulation of the immune response: theoretical basis and practical possibilities]. Medical Immunology (Russia). 2006;8(2–3):462–463. [Article in Russian].
- Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645-53.
- Zilber IE, Raspopina NA, Shuganov AE, Salmaci GN, Kazimirsky AN. [The analysis of an activation profile of lymphocytes at patients chronic obstructive illness of lungs in remission and an aggravation]. Zemskii Vrach. 2012(1):42-45. [Article in Russian].
- Filatov OYu, Kashaeva OV, Bugrimov DJu, Klimovich AA. [Morphophysiological principles of immunological effect of eukaryotic DNA]. Rossiiskii Immunologicheskii Zhurnal. 2013;7(4):385-90. [Article in Russian].
- Vollmer J, Weeratna RD, Jurk M, Samulowitz U, McCluskie MJ, Payette P, et al. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. Immunology. 2004;113(2):212-23.
- Vaĭnberg IP, Nosik DN, Kaplina EN, Nosik NN, Kalnina LB, Lavrukhina LA. [Action of drugs based on native DNA against RNA and DNA containing viruses]. Klin Med (Mosk). 1995;73(6):3-5.[Article in Russian].
- Global Initiative for Chronic Obstructive Lung Disease (GOLD, 2017 REPORT). Available from: http://goldcopd.org/
- Friemel H (ed). Immunological methods of work. 4th ed. Gustav Fischer Verlag, Jena;1991.
- Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992;145(6):1321-7.
- Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001;56(11):880-7.
- Jones P W. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002; 19(3):398–404.
- Chung KF. Measurement and assessment of cough and of the cough reflex. Eur Respir Rev. 2002;12(85):226-30.
Received August 23, 2019.
Accepted September 27, 2019.
©2019 International Medical Research and Development Corporation.